U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H27NO
Molecular Weight 309.4452
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHADONE

SMILES

CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=USSIQXCVUWKGNF-UHFFFAOYSA-N
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C21H27NO
Molecular Weight 309.4452
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf | https://www.drugs.com/pro/diskets.html

Methadone, sold under the brand names Dolophine among others, is an synthetic opioid that is used as the hydrochloride to treat pain and as maintenance therapy or to help with detoxification in people with opioid dependence. Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine. Some data also indicate that methadone acts as an antagonist at the NMDA-receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is unknown. Most common adverse reactions are: lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Avoid use mixed agonist/antagonist and partial agonist opioid analgesics with DOLOPHINE because they may reduce analgesic effect of DOLOPHINE or precipitate withdrawal symptoms.

CNS Activity

Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/5084666

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.51 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DOLOPHINE HYDROCHLORIDE

Approved Use

For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone.

Launch Date

-7.0649283E11
Palliative
DOLOPHINE HYDROCHLORIDE

Approved Use

For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone.

Launch Date

-7.0649283E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
548 ng/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
494 ng/mL
70 mg 1 times / day steady-state, oral
dose: 70 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
40.2 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
54 ng/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8.54 mg × h/L
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
8.27 μg × h/mL
70 mg 1 times / day steady-state, oral
dose: 70 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1073 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.61 mg × h/L
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.2 h
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
39 h
70 mg 1 times / day steady-state, oral
dose: 70 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
39.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Other AEs: Withdrawal syndrome neonatal...
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Respiratory depression, Addiction...
Other AEs:
Respiratory depression (grade 5)
Addiction
QT interval prolonged (grade 5)
Sources:
20 mg single, oral (starting)
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
unhealthy, adult
Other AEs: Respiratory depression, QT interval prolonged...
Other AEs:
Respiratory depression (grade 5)
QT interval prolonged
Arrhythmia (serious)
Sources:
AEs

AEs

AESignificanceDosePopulation
Withdrawal syndrome neonatal
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Addiction
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, adult
QT interval prolonged grade 5
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, adult
Respiratory depression grade 5
10 mg 3 times / day multiple, intravenous (starting)
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, adult
QT interval prolonged
20 mg single, oral (starting)
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
unhealthy, adult
Respiratory depression grade 5
20 mg single, oral (starting)
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
unhealthy, adult
Arrhythmia serious
20 mg single, oral (starting)
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
unhealthy, adult
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Enhanced treatment outcomes for cocaine-using methadone patients.
1999 May 3
[Fluoxetine (FX) efficacy in the treatment of cocaine dependence methadone maintenance patients. Interaction with plasma levels].
1999 Sep-Oct
Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance.
2000 Apr
Methadone, ciprofloxacin, and adverse drug reactions.
2000 Dec 16
Thrice-weekly versus daily buprenorphine maintenance.
2000 Jun 15
[Methadone withdrawal syndrome induced by nevirapine].
2000 Mar 18
Pain responses in methadone-maintained opioid abusers.
2000 Oct
The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment.
2000 Spring
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine.
2001 Aug
A case of a methadone-induced movement disorder.
2001 Dec
Enteral methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU.
2001 Dec
Family history influence on drug abuse severity and treatment outcome.
2001 Feb 1
Methadone-induced myoclonus in advanced cancer.
2001 Jan-Feb
Reversible delirium during opiod switching from transdermal fentanyl to methadone.
2001 Mar
Sleep-disordered breathing in stable methadone programme patients: a pilot study.
2001 Mar
Efficacy of an enteral 10-day methadone wean to prevent opioid withdrawal in fentanyl-tolerant pediatric intensive care unit patients.
2001 Oct
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.
2001 Oct 11
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
2002
Continuous epidural infusion of racemic methadone results in effective postoperative analgesia and low plasma concentrations.
2002 Jan
Bradycardia associated with intravenous methadone administered for sedation in a patient with acute respiratory distress syndrome.
2002 Sep
Bile duct dilation with chronic methadone use in asymptomatic patients: ERCP findings in 6 patients.
2003 Jul
Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
2003 Jun
Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin.
2003 Mar
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.
2003 Nov
QTc interval prolongation associated with intravenous methadone.
2003 Oct
Safety of injectable opioid maintenance treatment for heroin dependence.
2003 Oct 15
Methadone metabolism by human placenta.
2004 Aug 1
[Life-threatening, recurrent arrhythmia in patients on high-dose methadone treatment: torsade de pointes].
2004 Aug 30
Obsessive-compulsive symptoms precipitated by methadone tapering.
2004 Dec
Methadone-induced torsade de pointes in a patient with normal baseline QT interval.
2004 Jul-Aug
Directly observed therapy for the management of HIV-infected patients in a methadone program.
2004 Jun 1
Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
2004 Oct
Cocaine-related torsade de pointes in a methadone maintenance patient.
2005
QTc interval prolongation in patients on long-term methadone maintenance therapy.
2005
Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain.
2005 Apr
[Methadone-induced heart arrhythmia].
2005 Aug 11
Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver.
2005 Dec 12
Methadone-induced bradycardia.
2005 Jul
[Methadone and sleep apnea syndrome].
2005 Mar
Caution with nalbuphine in patients on long-term opioids.
2005 Mar
QT prolongation and syncope with methadone, doxepin, and a beta-blocker.
2005 Oct
Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients.
2006 Apr 28
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.
2006 Jan
Bradycardia during methadone therapy in an infant.
2006 Jan
A randomized controlled trial of interim methadone maintenance.
2006 Jan
Frequency of high-risk use of QT-prolonging medications.
2006 Jun
Patents

Sample Use Guides

Chronic pain: oral initial dose - 2.5 mg every 8 to 12 hours; Intravenous initial dose: 2.5 mg to 10 mg every 8 to 12 hours Opiate withdrawal: Initial dose - 20 to 30 mg orally; an additional 5 to 10 mg may be given orally after 2 to 4 hours if withdrawal symptoms have not been suppressed or if symptoms reappear. -Maximum initial dose: 30 mg -Maximum day 1 dose: 40 mg
Route of Administration: Other
In the presence of 1 uM methadone, the maximum 86Rb+ efflux stimulated by nicotine (Emax) was markedly reduced, but the EC50 for nicotine was altered only slightly, if at all.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:04:46 UTC 2023
Edited
by admin
on Fri Dec 15 15:04:46 UTC 2023
Record UNII
UC6VBE7V1Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHADONE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
METHADONE [MI]
Common Name English
DIAMINON
Common Name English
PHYSEPTONE
Common Name English
6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANONE
Systematic Name English
EPTADONE
Common Name English
METHADONE [VANDF]
Common Name English
METHADONE [HSDB]
Common Name English
HEPTADONE
Common Name English
DOLOPHIN
Common Name English
IDS-NM-002
Code English
DL-METHADONE
Common Name English
PHENADONE
Common Name English
METASEDIN
Common Name English
methadone [INN]
Common Name English
3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-
Systematic Name English
Methadone [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC N07BC02
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
NCI_THESAURUS C1506
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
NDF-RT N0000175684
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
WHO-ATC N02AC52
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
DEA NO. 9250
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
LIVERTOX NBK548084
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
WHO-VATC QN07BC02
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
CFR 21 CFR 862.3620
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 24.5
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
WHO-VATC QN02AC52
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
NDF-RT N0000175690
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
200-996-9
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
RXCUI
6813
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID7023273
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
SMS_ID
100000091046
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CHEBI
28017
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
MERCK INDEX
m7286
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C62044
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
HSDB
3119
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
EVMPD
SUB08833MIG
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
DRUG BANK
DB00333
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CHEBI
167309
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CHEBI
6807
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CAS
76-99-3
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
PUBCHEM
4095
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
ChEMBL
CHEMBL651
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
MESH
D008691
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
INN
788
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
DAILYMED
UC6VBE7V1Z
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
FDA UNII
UC6VBE7V1Z
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
LACTMED
Methadone
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
IUPHAR
5458
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
DRUG CENTRAL
1728
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CHEBI
50140
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
WIKIPEDIA
METHADONE
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
PRIMARY
CAS
297-88-1
Created by admin on Fri Dec 15 15:04:46 UTC 2023 , Edited by admin on Fri Dec 15 15:04:46 UTC 2023
SUPERSEDED
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
CYP2C19 preferentially metabolized (R)-methadone,
METABOLIC ENZYME -> SUBSTRATE
CYP2B6 preferentially metabolized (S)-methadone,
PARENT -> SALT/SOLVATE
TARGET->ANTAGONIST
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
CYP3A4 showed no preference between the two enantiomers
ACTIVE ENANTIOMER->RACEMATE
approximately 50x the potency of the S-(+)-enantiomer as well as greater μ-opioid receptor selectivity
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
The hierarchy of EDDPgeneration was CYP2B6 > CYP2C19zCYP3A4
MAJOR
PARENT -> METABOLITE
MINOR
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
5-10% of the dose but there is a large individual variation due to pH, urine volume, dose and metabolic rate
MINOR
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC